181 related articles for article (PubMed ID: 28557458)
1. Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.
Nishiguchi GA; Rico A; Tanner H; Aversa RJ; Taft BR; Subramanian S; Setti L; Burger MT; Wan L; Tamez V; Smith A; Lou Y; Barsanti PA; Appleton BA; Mamo M; Tandeske L; Dix I; Tellew JE; Huang S; Mathews Griner LA; Cooke VG; Van Abbema A; Merritt H; Ma S; Gampa K; Feng F; Yuan J; Wang Y; Haling JR; Vaziri S; Hekmat-Nejad M; Jansen JM; Polyakov V; Zang R; Sethuraman V; Amiri P; Singh M; Lees E; Shao W; Stuart DD; Dillon MP; Ramurthy S
J Med Chem; 2017 Jun; 60(12):4869-4881. PubMed ID: 28557458
[TBL] [Abstract][Full Text] [Related]
2. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
Shao W; Mishina YM; Feng Y; Caponigro G; Cooke VG; Rivera S; Wang Y; Shen F; Korn JM; Mathews Griner LA; Nishiguchi G; Rico A; Tellew J; Haling JR; Aversa R; Polyakov V; Zang R; Hekmat-Nejad M; Amiri P; Singh M; Keen N; Dillon MP; Lees E; Ramurthy S; Sellers WR; Stuart DD
Cancer Res; 2018 Mar; 78(6):1537-1548. PubMed ID: 29343524
[TBL] [Abstract][Full Text] [Related]
3. Design and Discovery of
Ramurthy S; Taft BR; Aversa RJ; Barsanti PA; Burger MT; Lou Y; Nishiguchi GA; Rico A; Setti L; Smith A; Subramanian S; Tamez V; Tanner H; Wan L; Hu C; Appleton BA; Mamo M; Tandeske L; Tellew JE; Huang S; Yue Q; Chaudhary A; Tian H; Iyer R; Hassan AQ; Mathews Griner LA; La Bonte LR; Cooke VG; Van Abbema A; Merritt H; Gampa K; Feng F; Yuan J; Mishina Y; Wang Y; Haling JR; Vaziri S; Hekmat-Nejad M; Polyakov V; Zang R; Sethuraman V; Amiri P; Singh M; Sellers WR; Lees E; Shao W; Dillon MP; Stuart DD
J Med Chem; 2020 Mar; 63(5):2013-2027. PubMed ID: 31059256
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
Henry JR; Kaufman MD; Peng SB; Ahn YM; Caldwell TM; Vogeti L; Telikepalli H; Lu WP; Hood MM; Rutkoski TJ; Smith BD; Vogeti S; Miller D; Wise SC; Chun L; Zhang X; Zhang Y; Kays L; Hipskind PA; Wrobleski AD; Lobb KL; Clay JM; Cohen JD; Walgren JL; McCann D; Patel P; Clawson DK; Guo S; Manglicmot D; Groshong C; Logan C; Starling JJ; Flynn DL
J Med Chem; 2015 May; 58(10):4165-79. PubMed ID: 25965804
[TBL] [Abstract][Full Text] [Related]
5. Discovery of spiro amide SHR902275: A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers.
Zhao P; Zhuang L; Wang X; Huang S; Wu H; Zhou Y; Yan Y; Zhang F; Shen R; Li J; Liu S; Zhang R; Dong P; Mao Y; Fan Y; He C; Sun J; Zhang L; Hu Q; Wan H; Feng J; Bai C; He F; Tao W
Eur J Med Chem; 2022 Jan; 228():114040. PubMed ID: 34906761
[TBL] [Abstract][Full Text] [Related]
6. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
7. LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
Monaco KA; Delach S; Yuan J; Mishina Y; Fordjour P; Labrot E; McKay D; Guo R; Higgins S; Wang HQ; Liang J; Bui K; Green J; Aspesi P; Ambrose J; Mapa F; Griner L; Jaskelioff M; Fuller J; Crawford K; Pardee G; Widger S; Hammerman PS; Engelman JA; Stuart DD; Cooke VG; Caponigro G
Clin Cancer Res; 2021 Apr; 27(7):2061-2073. PubMed ID: 33355204
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
Hong SP; Ahn SK
Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
[TBL] [Abstract][Full Text] [Related]
9. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
[TBL] [Abstract][Full Text] [Related]
10. Potent and selective pyrazole-based inhibitors of B-Raf kinase.
Hansen JD; Grina J; Newhouse B; Welch M; Topalov G; Littman N; Callejo M; Gloor S; Martinson M; Laird E; Brandhuber BJ; Vigers G; Morales T; Woessner R; Randolph N; Lyssikatos J; Olivero A
Bioorg Med Chem Lett; 2008 Aug; 18(16):4692-5. PubMed ID: 18676143
[TBL] [Abstract][Full Text] [Related]
11. Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.
Yurugi H; Marini F; Weber C; David K; Zhao Q; Binder H; Désaubry L; Rajalingam K
Oncogene; 2017 Aug; 36(33):4778-4789. PubMed ID: 28414306
[TBL] [Abstract][Full Text] [Related]
12. Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-Raf(V600E) kinase.
Wenglowsky S; Ren L; Grina J; Hansen JD; Laird ER; Moreno D; Dinkel V; Gloor SL; Hastings G; Rana S; Rasor K; Sturgis HL; Voegtli WC; Vigers G; Willis B; Mathieu S; Rudolph J
Bioorg Med Chem Lett; 2014 Apr; 24(8):1923-7. PubMed ID: 24675381
[TBL] [Abstract][Full Text] [Related]
13. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
Wang X; Allen S; Blake JF; Bowcut V; Briere DM; Calinisan A; Dahlke JR; Fell JB; Fischer JP; Gunn RJ; Hallin J; Laguer J; Lawson JD; Medwid J; Newhouse B; Nguyen P; O'Leary JM; Olson P; Pajk S; Rahbaek L; Rodriguez M; Smith CR; Tang TP; Thomas NC; Vanderpool D; Vigers GP; Christensen JG; Marx MA
J Med Chem; 2022 Feb; 65(4):3123-3133. PubMed ID: 34889605
[TBL] [Abstract][Full Text] [Related]
14. Identification and Biological Evaluation of Novel Type II B-Raf
Wang PF; Wang ZF; Qiu HY; Huang Y; Hu HM; Wang ZC; Zhu HL
ChemMedChem; 2018 Dec; 13(23):2558-2566. PubMed ID: 30353975
[TBL] [Abstract][Full Text] [Related]
15. Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors.
Pasquier B; El-Ahmad Y; Filoche-Rommé B; Dureuil C; Fassy F; Abecassis PY; Mathieu M; Bertrand T; Benard T; Barrière C; El Batti S; Letallec JP; Sonnefraud V; Brollo M; Delbarre L; Loyau V; Pilorge F; Bertin L; Richepin P; Arigon J; Labrosse JR; Clément J; Durand F; Combet R; Perraut P; Leroy V; Gay F; Lefrançois D; Bretin F; Marquette JP; Michot N; Caron A; Castell C; Schio L; McCort G; Goulaouic H; Garcia-Echeverria C; Ronan B
J Med Chem; 2015 Jan; 58(1):376-400. PubMed ID: 25402320
[TBL] [Abstract][Full Text] [Related]
16. Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3
Huestis MP; Dela Cruz D; DiPasquale AG; Durk MR; Eigenbrot C; Gibbons P; Gobbi A; Hunsaker TL; La H; Leung DH; Liu W; Malek S; Merchant M; Moffat JG; Muli CS; Orr CJ; Parr BT; Shanahan F; Sneeringer CJ; Wang W; Yen I; Yin J; Siu M; Rudolph J
J Med Chem; 2021 Apr; 64(7):3940-3955. PubMed ID: 33780623
[TBL] [Abstract][Full Text] [Related]
17. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds.
Okaniwa M; Hirose M; Imada T; Ohashi T; Hayashi Y; Miyazaki T; Arita T; Yabuki M; Kakoi K; Kato J; Takagi T; Kawamoto T; Yao S; Sumita A; Tsutsumi S; Tottori T; Oki H; Sang BC; Yano J; Aertgeerts K; Yoshida S; Ishikawa T
J Med Chem; 2012 Apr; 55(7):3452-78. PubMed ID: 22376051
[TBL] [Abstract][Full Text] [Related]
19. Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.
Gould AE; Adams R; Adhikari S; Aertgeerts K; Afroze R; Blackburn C; Calderwood EF; Chau R; Chouitar J; Duffey MO; England DB; Farrer C; Forsyth N; Garcia K; Gaulin J; Greenspan PD; Guo R; Harrison SJ; Huang SC; Iartchouk N; Janowick D; Kim MS; Kulkarni B; Langston SP; Liu JX; Ma LT; Menon S; Mizutani H; Paske E; Renou CC; Rezaei M; Rowland RS; Sintchak MD; Smith MD; Stroud SG; Tregay M; Tian Y; Veiby OP; Vos TJ; Vyskocil S; Williams J; Xu T; Yang JJ; Yano J; Zeng H; Zhang DM; Zhang Q; Galvin KM
J Med Chem; 2011 Mar; 54(6):1836-46. PubMed ID: 21341678
[TBL] [Abstract][Full Text] [Related]
20. Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.
Mathieu S; Gradl SN; Ren L; Wen Z; Aliagas I; Gunzner-Toste J; Lee W; Pulk R; Zhao G; Alicke B; Boggs JW; Buckmelter AJ; Choo EF; Dinkel V; Gloor SL; Gould SE; Hansen JD; Hastings G; Hatzivassiliou G; Laird ER; Moreno D; Ran Y; Voegtli WC; Wenglowsky S; Grina J; Rudolph J
J Med Chem; 2012 Mar; 55(6):2869-81. PubMed ID: 22335519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
